Ikeda Yasuhiko, Kuroda Taisuke, Mita Hiroshi, Tamura Norihisa, Ohta Minoru
Equestrian Park, Japan Racing Association, Tokyo, Japan.
Equine Research Institute, Japan Racing Association, Tochigi, Japan.
J Vet Med Sci. 2025 Feb 4;87(2):171-174. doi: 10.1292/jvms.24-0412. Epub 2025 Jan 14.
We compared the antihistamine effect of four new antihistamines with olopatadine, which is used to treat equine allergic diseases. Six healthy Thoroughbred horses received oral doses of olopatadine (50 mg), levocetirizine (50 mg), bilastine (200 mg), rupatadine (100 mg), and desloratadine (50 mg) at >2-week intervals. The effects were investigated by measurement of the wheal area induced by histamine intradermal injection, and inhibition rate was compared with positive and negative controls. The maximum wheal inhibition rate (mean ± SD) of olopatadine (85.3% ± 7.7%) was significantly higher than those of bilastine (51.1% ± 11.8%), rupatadine (55.3% ± 6.6%), and desloratadine (59.8% ± 6.4%), but not levocetirizine (85.4% ± 8.0%). Levocetirizine is expected to have a high antihistamine effect on horses.
我们将四种新型抗组胺药的抗组胺作用与用于治疗马过敏性疾病的奥洛他定进行了比较。六匹健康的纯种马以大于两周的间隔口服奥洛他定（50毫克）、左西替利嗪（50毫克）、比拉斯汀（200毫克）、卢帕他定（100毫克）和地氯雷他定（50毫克）。通过测量组胺皮内注射诱导的风团面积来研究其效果，并将抑制率与阳性和阴性对照进行比较。奥洛他定的最大风团抑制率（平均值±标准差）为85.3%±7.7%，显著高于比拉斯汀（51.1%±11.8%）、卢帕他定（55.3%±6.6%）和地氯雷他定（59.8%±6.4%），但不高于左西替利嗪（85.4%±8.0%）。预计左西替利嗪对马具有较高的抗组胺作用。
